Fig. 4From: Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?Expected event-free survival curves for trastuzumab as well as for the combination of trastuzumab and lapatinib are shown based on the NeoALTTO results. (Reproduced with permission from Clinical Cancer Research, DeMichele et al. [41]: License Number 3666990663029)Back to article page